Research funding and price negotiation for new drugs

Barigozzi, Francesca; Jelovac, Izabela

Research funding and price negotiation for new drugs

Francesca Barigozzi and Izabela Jelovac

No 1901, Working Papers from Groupe d'Analyse et de Théorie Economique Lyon St-Étienne (GATE Lyon St-Étienne), Université de Lyon

Abstract: Pharmaceutical innovations result from the successful achievement of basic research, produced by an upstream lab, and applied research, produced by a downstream lab. We focus on the negotiation process to finance basic research by setting public and private grants and to agree on the final price of a new drug. We show that exclusive funding of basic research is desirable. To increase consumers’ surplus and reduce negotiated prices for new drugs, basic and applied research should be integrated if the lab producing applied research has a relatively large bargaining power. When instead the health authority has the larger bargaining power, integration with the producer of basic research increases negotiated prices for new drugs and should be avoided, unless the gain in bargaining power after the integration is extremely high.

Keywords: Pharmaceutical innovation; drug prices; negotiation; basic research; applied research (search for similar items in EconPapers)
JEL-codes: D8 (search for similar items in EconPapers)
Date: 2019
New Economics Papers: this item is included in nep-com, nep-hea, nep-ind, nep-ino and nep-mic
References: Add references at CitEc
Citations:

Downloads: (external link)
ftp://ftp.gate.cnrs.fr/RePEc/2019/1902.pdf (application/pdf)

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gat:wpaper:1902

Access Statistics for this paper

More papers in Working Papers from Groupe d'Analyse et de Théorie Economique Lyon St-Étienne (GATE Lyon St-Étienne), Université de Lyon Contact information at EDIRC.
Bibliographic data for series maintained by Nelly Wirth ( this e-mail address is bad, please contact ).